| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BBT-877 | BBT-877 | Phase 2 Clinical | Legochem | Idiopathic Pulmonary Fibrosis | Details |
| Cambritaxestat | IOA-289 | Phase 2 Clinical | Merck & Co, Cancer Research Technology | Solid tumours; Pancreatic Neoplasms | Details |
| Ziritaxestat | GLPG-1690 | Phase 2 Clinical | Galapagos Nv | Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic | Details |
| HNC664 | HNC664; HNC-664 | Phase 1 Clinical | Guangzhou Henovcom Bioscience Co Ltd | Pancreatic Neoplasms; Idiopathic Pulmonary Fibrosis | Details |
| Cudetaxestat | PAT-409; BLD-0409 | Phase 1 Clinical | Blade Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Idiopathic Pulmonary Fibrosis; Liver Diseases | Details |
| HNC-1058 | HNC-1058 | Phase 1 Clinical | Guangzhou Henovcom Bioscience Co Ltd | Idiopathic Pulmonary Fibrosis | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



